FDA Alerts

The FDA announced that a new hyaluronic acid dermal filler is now approved for cheek augmentation and for correction of midface contour deficiencies in adults aged 21 years or older.

The FDA announced approval of a new bioengineered allogeneic cellularized construct for the treatment of deep partial-thickness thermal burns.

The FDA announced approval of secukinumab, an IL-17 inhibitor, for the treatment of moderate to severe plaque psoriasis in patients aged 6 years and older. The approved dosing is 75 mg or 150 mg, dependent on the child’s weight at dosing...

The FDA announced approval of cemiplimab-rwlc for basal cell carcinoma (BCC), giving dermatologists managing locally advanced and metastatic BCC now have another option in their toolbox.

The FDA announced that ligelizumab has received the Breakthrough Therapy designation for the treatment of chronic spontaneous urticaria for patients who have had an inadequate response to H1-antihistamines.

The FDA announced its latest dermatologic therapy approval of over-the-counter (OTC) ivermectin lotion 0.5% for the treatment of head lice infestation in patients 6 months of age and older. Ivermectin lotion, 0.5%,...